2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
02:45 p.m. - 04:15 p.m.
MCCNO - 353-355
Technology and Procedures, Assays, Molecular Testing, Treatment Considerations, Women’s Health, Workforce, Artificial Intelligence (AI), Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Diseases, Bone Marrow Failure Syndromes, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, Research, AML, Clinical Research, Study Population, Human
PAPER

945 Hope for parenthood: Pregnancy outcomes after ATG-based haploidentical hematopoietic stem cell transplantation using nationally representative data

Qiu-Sha Huang, MD, Meng-Ya Yang2, Yuanyuan Zhang3, Yuhong Chen4, Yao Chen, MD5, Huan Chen6, Jingzhi Wang7, Hai-Xia Fu, MD8, Ting-ting Han, MD9, Chen-hua Yan10, Zhi-Dong Wang11, Fengrong Wang12, Jun Kong, MD13, Wei Han14, Xiao-Dong Mo, MD15, Yifei Cheng16, yuqian Sun17, Meng Lv18, Liping Dou, MD19, Xi Zhang, MD20, Huang Xiaobing21, Yajing Xu22, Linghui Xia23, Shun-Qing Wang24, Yehui Tan25, Yi Chen26, Fang Zhou27, Fei Li, MD, PhD28, Weiwei Qin, MD29, Ying Lu30, Qike Zhang, MD31, Jia Feng32, Lei Fan, MD33, Xiangxiang Zhou34, Weiwei Tian, MD, PhD35, Yu Wang36, Lanping Xu, MD37, Xiaojun Huang, MD, PhD38, Xiaohui Zhang, MD39
1 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
2 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
3 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
4 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
5 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
6 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
7 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
8 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
9 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
10 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
11 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
12 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
13 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
14 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
15 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
16 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
17 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
18 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
19 Chinese PLA General Hospital, Beijing, China
20 Xinqiao Hospital of Army Medical University, Chongqing, China
21 Sichuan Provincial People's Hospital, Chengdu, China
22 Xiangya Hospital of Central South University, Changsha, China
23 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
24 Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China
25 The First Hospital of Jilin University, Changchun, China
26 The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
27 The 960th hospital of the PLA joint logistscs support force, Jinan, China
28 The First Affiliated Hospital of Nanchang University, Nanchang, China
29 Tangdu Hospital Fourth Military Medical University, Xi'an, China
30 The Affiliated People's Hospital of Ningbo University, Ningbo, China
31 Gansu Provincial Hospital, Lanzhou, China
32 Peking University Shenzhen Hospital, Shenzhen, China
33 Jiangsu Province Hospital, Nanjing, China
34 Provincial Hospital Affiliated to Shandong University, Jinan, China
35 Shanxi Bethune Hospital, Taiyuan, China
36 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
37 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People’s Hospital, Beijing, China
38 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People’s Hospital, Beijing, China
39 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China

Background: Allogeneic hematopoietic stem cell transplantation (HSCT) has improved long-term survival, making parenthood an important goal for young survivors. However, treatment-related infertility risk poses challenges. In China, haploidentical transplantation now dominates (>60%), predominantly using ATG-based conditioning, but its effects on fertility, pregnancy, and long-term offspring health in adolescents and young adults remain unknown. We therefore established the largest cohort in a nationwide multicenter study with long-term follow-up to evaluate pregnancy outcomes, including live birth rates, maternal complications, and long-term offspring health after haploidentical HSCT.

Methods: This national multicenter retrospective cohort study included 18 transplant centers across China. Eligible patients were female recipients aged < 40 years and male recipients aged < 45 years whose partners subsequently conceived, all of whom underwent haploidentical HSCT between 2005 and 2024 and survived ≥ 2 years post-transplant. Cumulative incidence of first pregnancy and first live birth were estimated using the Aalen-Johansen estimator with death as competing risk. Multivariable Poisson regression was used to identify factors associated with live birth.

Results: Among 7200 eligible patients (4086 males, 3114 females), 121 pregnancies were reported in 108 patients (1.5% of the cohort): 48 pregnancies in 45 female recipients (1.4%) and 73 pregnancies in partners of 63 male recipients (1.5%). The median length of follow-up was 8.1 (6.0-15.6) years. Median age at transplant was 23 years (range 16–38) for females and 26 years (range 18–40) for males. Underlying diseases included acute leukemia (52%), aplastic anemia (28%), and MDS (20%). All patients received BU/CY+ATG as conditioning.

Pregnancy incidence was consistently higher among partners of male recipients than female recipients across all time points: cumulative incidence of first pregnancy at 5 years was 1.9% vs 1.8%, and at 10 years was 3.3% vs 3.1%. Median time from transplant to first pregnancy was 5.8 years (range 1.4–14.8) for male recipients' partners and 5.2 years (range 0.8–12.0) for female recipients. Overall, the annual first pregnancy rate was 0.48% and the annual first live birth rate was 0.39%. Multivariable analysis identified younger age, male sex, and non-malignant disease as independent predictors of higher pregnancy rates. Chronic GVHD of any severity was not significantly associated with reduced live birth (RR 0.74, 95% CI 0.38–1.44, P=0.37).

Among 121 pregnancies, 83.3% occurred spontaneously and 16.7% were achieved through assisted reproductive technologies (including IVF, sperm/oocyte cryopreservation, ovarian tissue reimplantation, and oocyte donation). The live birth rate among all pregnancies was 84.3% (102/121); 4 pregnancies ended in miscarriage (3.3%), none in stillbirth, 15 were either ongoing at last follow-up or electively terminated. Preterm delivery (< 37 weeks) occurred in 5.9% of live births and low birth weight in 2.9%, comparable to general population rates in China. Maternal complications were documented in 12.0% of pregnancies, with gestational diabetes (8.3%) being most common, followed by hypertensive disorders (5.8%, including pre-eclampsia and pregnancy-induced hypertension). No maternal deaths occurred. With median offspring follow-up of 4.2 years, no congenital anomalies were reported; 88% of mothers rated their children's physical and mental development as age-appropriate.

Conclusions: This is the first study to evaluate pregnancy outcomes after haploidentical HSCT in a nationally representative cohort. Our findings underscore that parenthood is achievable in haploidentical recipients, with over two-thirds of pregnancies occurring spontaneously. Assisted reproductive technologies are important and should be made available, yet the potential for spontaneous pregnancies should not be underestimated, and patients should be informed of the possibility of unexpected pregnancy despite reduced fertility. Fertility preservation strategies and routine reproductive counseling should be offered both before and after transplant. Fertility and outcomes of pregnancy after haploidentical HSCT need prospective validation in large transplant cohorts.

Qiu-Sha Huang, MD: No relevant conflicts of interest to declare.